Organogenesis Holdings (ORGO) Cash from Financing Activities (2016 - 2026)

Organogenesis Holdings' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 883.12% year-over-year to -$20.2 million in Q1 2026; TTM through Mar 2026 was -$35.5 million, a 226.0% decrease from a year earlier, with the FY2025 full-year figure at -$17.4 million, down 162.81% from the prior year.
• Cash from Financing Activities fell to -$20.2 million in Q1 2026 per ORGO's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $33.6 million in Q4 2024 and bottomed at -$20.2 million in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$1.7 million (2024), against an average of -$1.0 million.
• Across the five-year window, Cash from Financing Activities sank 5630.77% in 2023 and soared 1993.58% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$1.9 million in 2022, then gained by 5.23% to -$1.8 million in 2023, then surged by 1993.58% to $33.6 million in 2024, then tumbled by 114.29% to -$4.8 million in 2025, then slumped by 320.32% to -$20.2 million in 2026.
• Per Business Quant, the three latest ORGO Cash from Financing Activities figures stand at -$20.2 million (Q1 2026), -$4.8 million (Q4 2025), and -$10.2 million (Q3 2025).